Immunopathology and Immunotherapy of Inflammatory Skin Diseases

키워드

참고문헌 (132)

1. Greb JE, "Psoriasis", Nat Rev Dis Primers, 2, pp.16082~ (2016)
2. Alinaghi F, "Prevalence of psoriatic arthritis in patients with psoriasis : a systematic review and metaanalysis of observational and clinical studies", J Am Acad Dermatol, 80, pp.251~265 (2019)
3. Heydendael VM, "Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis", N Engl J Med, 349, pp.658~665 (2003)
4. Lee E, "Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris", J Exp Med, 199, pp.125~130 (2004)
5. Nair RP, "Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways", Nat Genet, 41, pp.199~204 (2009)
6. Ghoreschi K, "Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis", Lancet, 397, pp.754~766 (2021)
7. Nair RP, "Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1gene", Am J Hum Genet, 78, pp.827~851 (2006)
8. Arakawa A, "Melanocyte antigen triggers autoimmunity in human psoriasis", J Exp Med, 212, pp.2203~2212 (2015)
9. Lande R, "The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis", Nat Commun, 5, pp.5621~ (2014)
10. Kim JH, "Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17a production from programmed cell death 1-high T cells", J Allergy Clin Immunol, 137, pp.1466~1476 (2016)
11. Nakamizo S, "Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis", J Exp Med, 218, pp.218~ (2021)
12. Moos S, "Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes", J Invest Dermatol, 139, pp.1110~1117 (2019)
13. Kim TG, "Dermal clusters of mature dendritic cells and T cells are associated with the CCL20", CCR6chemokine system in chronic psoriasis, 2014, pp.134, 1462~1465
14. Leonardi CL, "Etanercept as monotherapy in patients with psoriasis", N Engl J Med, 349, pp.2014~2022 (2003)
15. Griffiths CE, "Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis", N Engl J Med, 362, pp.118~128 (2010)
16. Gordon KB, "Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis(UltIMMa-1 and UltIMMa-2) : results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials", Lancet, 392, pp.650~661 (2018)
17. Diels J, "Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis : the COMPASS analysis", Br J Dermatol, 183, pp.276~284 (2020)
18. Sbidian E, "Systemic pharmacological treatments for chronic plaque psoriasis : a network meta-analysis", Cochrane Database Syst Rev, 4, pp.CD011535~ (2021)
19. Thaçi D, "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis : CLEAR, a randomized controlled trial", J Am Acad Dermatol, 73, pp.400~409 (2015)
20. Reich K, "Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis : 24-week results from IXORA-S, a phase III study", Br J Dermatol, 177, pp.1014~1023 (2017)
21. Lebwohl M, "Phase 3 studies comparing brodalumab with ustekinumab in psoriasis", N Engl J Med, 373, pp.1318~1328 (2015)
22. Reich K, "Bimekizumab versus secukinumab in plaque psoriasis", N Engl J Med, 385, pp.142~152 (2021)
23. Papp K, "Phase 2trial of selective tyrosine kinase 2 inhibition in psoriasis", N Engl J Med, 379, pp.1313~1321 (2018)
24. Forman SB, "Tyk2", JAK1 inhibitor PF-06700841 in patients with plaque psoriasis : phase IIa, randomized, double-blind, placebo-controlled trial, 2020, pp.140, 2359~2370
25. Murphrey M, "Special editorial : when prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the fda’s 9", 1, J Am Acad Dermatol, pp.2022 (2021), 86[DOI]
26. Langan SM, "Atopic dermatitis", Lancet, 396, pp.345~360 (2020)
27. Abuabara K, "Patterns and predictors of atopic dermatitis disease control past childhood : an observational cohort study", J Allergy Clin Immunol, 141, pp.778~780 (2018)
28. Abuabara K, "The prevalence of atopic dermatitis beyond childhood : a systematic review and meta-analysis of longitudinal studies", Allergy, 73, pp.696~704 (2018)
29. Sandilands A, "Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema", Nat Genet, 39, pp.650~654 (2007)
30. Bieber T, "Atopic dermatitis : an expanding therapeutic pipeline for a complex disease", Nat Rev Drug Discov, 21, pp.21~40 (2021)
31. Yang L, "Research progress in atopic march", Front Immunol, 11, pp.1907~ (2020)
32. Byrd AL, "The human skin microbiome", Nat Rev Microbiol, 16, pp.143~155 (2018)
33. Zipperer A, "Human commensals producing a novel antibiotic impair pathogen colonization", Nature, 535, pp.511~516 (2016)
34. Kobayashi T, "Dysbiosis and staphylococcus aureus colonization drives inflammation in atopic dermatitis", Immunity, 42, pp.756~766 (2015)
35. Yoshida K, "Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis", J Allergy Clin Immunol, 134, pp.856~864 (2014)
36. Hammad H, "Barrier epithelial cells and the control of type 2 immunity", Immunity, 43, pp.29~40 (2015)
37. Gandhi NA, "Targeting key proximal drivers of type 2 inflammation in disease", Nat Rev Drug Discov, 15, pp.35~50 (2016)
38. Lee Seung-Ju, "Dupilumab Therapy Improves Stratum Corneum Hydration and Skin Dysbiosis in Patients With Atopic Dermatitis", Allergy, Asthma & Immunology Research, 13(5), pp.762~775 (2021), 대한천식알레르기학회[DOI]
39. 진미림, "From Bench to Clinic: the Potential of Therapeutic Targeting of the IL-22 Signaling Pathway in Atopic Dermatitis", Immune Network, 18(6), pp.1~11 (2018), 대한면역학회[DOI]
40. Oetjen LK, "Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch", Cell, 171, pp.217~228 (2017)
41. Trier AM, "IL-33 signaling in sensory neurons promotes dry skin itch", J Allergy Clin Immunol (2021)[DOI]
42. Simon D, "Eosinophils and atopic dermatitis", Allergy, 59, pp.561~570 (2004)
43. Wang F, "A basophil-neuronal axis promotes itch", Cell, 184, pp.422~440 (2021)
44. 이지현, "Consensus Update for Systemic Treatment of Atopic Dermatitis", Annals of Dermatology, 33(6), pp.497~514 (2021), 대한피부과학회[DOI]
45. Simpson EL, "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis", N Engl J Med, 375, pp.2335~2348 (2016)
46. Gooderham MJ, "Dupilumab : a review of its use in the treatment of atopic dermatitis", J Am Acad Dermatol, 78(Suppl 1), pp.S28~S36 (2018)
47. Beck LA, "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis", N Engl J Med, 371, pp.130~139 (2014)
48. Schneeweiss MC, "Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis : a propensity score-matched cohort study", J Am Acad Dermatol, 84, pp.300~311 (2021)
49. Wollenberg A, "Tralokinumab for moderate-to-severe atopic dermatitis : results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials(ECZTRA 1 and ECZTRA 2)", Br J Dermatol, 184, pp.437~449 (2021)
50. Reich K, "Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis(AD Up) : results from a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 397, pp.2169~2181 (2021)
51. Guttman-Yassky E, "Once-daily upadacitinib versus placebo in adolescents and adults with moderateto-severe atopic dermatitis(Measure Up 1 and Measure Up 2) : results from two replicate double-blind, randomised controlled phase 3 trials", Lancet, 397, pp.2151~2168 (2021)
52. Blauvelt A, "Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis : a randomized clinical trial", JAMA Dermatol, 157, pp.1047~1055 (2021)
53. Simpson EL, "Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids : results from two randomized monotherapy phase III trials", Br J Dermatol, 183, pp.242~255 (2020)
54. Papp K, "Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis : results from 2 phase 3, randomized, double-blind studies", J Am Acad Dermatol, 85, pp.863~872 (2021)
55. Nakagawa H, "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis : a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study", J Am Acad Dermatol, 82, pp.823~831 (2020)
56. Kabashima K, "Trial of nemolizumab and topical agents for atopic dermatitis with pruritus", N Engl J Med, 383, pp.141~150 (2020)
57. Simpson EL, "Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis(JADE MONO-1) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial", Lancet, 396, pp.255~266 (2020)
58. Amagai M, "Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion", Cell, 67, pp.869~877 (1991)
59. Mahoney MG, "Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris", J Clin Invest, 103, pp.461~468 (1999)
60. Samuelov L, "Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting", Nat Genet, 45, pp.1244~1248 (2013)
61. Kim JH, "A homozygous nonsense mutation in the dsg3 gene causes acantholytic blisters in the oral and laryngeal mucosa", J Invest Dermatol, 139, pp.1187~1190 (2019)
62. Amagai M, "Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3for serodiagnosis of pemphigus", Br J Dermatol, 140, pp.351~357 (1999)
63. Payne AS, "Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display", J Clin Invest, 115, pp.888~899 (2005)
64. Kasperkiewicz M, "Pemphigus", Nat Rev Dis Primers, 3, pp.17026~ (2017)
65. Cho A, "Single-cell analysis suggests that ongoing affinity maturation drives the emergence of pemphigus vulgaris autoimmune disease", Cell Rep, 28, pp.909~922 (2019)
66. Cho MJ, "Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients", Nat Commun, 5, pp.4167~ (2014)
67. Kim AR, "Targeting inducible costimulator expressed on cxcr5(+)pd-1(+)th cells suppresses the progression of pemphigus vulgaris", J Allergy Clin Immunol, 146, pp.1070~1079 (2020)
68. Holstein J, "Immunophenotyping in pemphigus reveals a TH17", TFH17 cell-dominated immune response promoting desmoglein1, J Allergy Clin Immunol, pp.2021, 147[DOI]
69. Kim MR, "Long-term prognosis of pemphigus in Korea : retrospective analysis of 199patients", Dermatology, 223, pp.182~188 (2011)
70. Amagai M, "A randomized double-blind trial of intravenous immunoglobulin for pemphigus", J Am Acad Dermatol, 60, pp.595~603 (2009)
71. Joly P, "A single cycle of rituximab for the treatment of severe pemphigus", N Engl J Med, 357, pp.545~552 (2007)
72. Kim JH, "Clinical efficacy of different doses of rituximab in the treatment of pemphigus : a retrospective study of 27 patients", Br J Dermatol, 165, pp.646~651 (2011)
73. Werth VP, "Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris", N Engl J Med, 384, pp.2295~2305 (2021)
74. Wang HH, "Efficacy of rituximab for pemphigus : a systematic review and metaanalysis of different regimens", Acta Derm Venereol, 95, pp.928~932 (2015)
75. Joly P, "First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus(Ritux 3) : a prospective, multicentre, parallel-group, open-label randomised trial", Lancet, 389, pp.2031~2040 (2017)
76. Schmidt E, "Pemphigus", Lancet, 394, pp.882~894 (2019)
77. Ellebrecht CT, "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease", Science, 353, pp.179~184 (2016)
78. Lee J, "Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris", J Clin Invest, 130, pp.6317~6324 (2020)
79. Murrell DF, "Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris : the phase II BELIEVE study", Br J Dermatol, 185, pp.745~755 (2021)
80. Yamagami J, "A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton’s tyrosine kinase inhibitor, in pemphigus", J Dermatol Sci, 103, pp.135~142 (2021)
81. Goebeler M, "Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial", Br J Dermatol (2021)[DOI]
82. Werth VP, "Safety, tolerability, and activity of alxn1830 targeting the neonatal fc receptor in chronic pemphigus", J Invest Dermatol, 141, pp.2858~2865 (2021)
83. Lee H, "Evaluation of risk of bullous pemphigoid with initiation of dipeptidyl peptidase-4 inhibitor vs second-generation sulfonylurea", JAMA Dermatol, 156, pp.1107~1114 (2020)
84. Wongvibulsin S, "Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors : a United States population-level analysis", J Am Acad Dermatol (2021)[DOI]
85. Lai YC, "Bullous pemphigoid and its association with neurological diseases : a systematic review and meta-analysis", J Eur Acad Dermatol Venereol, 30, pp.2007~2015 (2016)
86. Tedbirt B, "Mixed individual-aggregate data on all-cause mortality in bullous pemphigoid : a meta-analysis", JAMA Dermatol, 157, pp.421~430 (2021)
87. Kobayashi M, "BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid", J Dermatol Sci, 30, pp.224~232 (2002)
88. van Beek N, "Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity", JAMA Dermatol, 153, pp.30~38 (2017)
89. Nishie W, "Humanization of autoantigen", Nat Med, 13, pp.378~383 (2007)
90. Fairley JA, "A pathogenic role for IgE in autoimmunity : bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu", nu mice, 2007, pp.127, 2605~2611
91. Nelson KC, "Role of different pathways of the complement cascade in experimental bullous pemphigoid", J Clin Invest, 116, pp.2892~2900 (2006)
92. Leyendeckers H, "Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies", J Invest Dermatol, 120, pp.372~378 (2003)
93. Liu Z, "Dysfunction of CD19+CD24hiCD27+ B regulatory cells in patients with bullous pemphigoid", Sci Rep, 8, pp.703~ (2018)
94. Muramatsu K, "Regulatory t-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects", J Allergy Clin Immunol, 142, pp.1818~1830 (2018)
95. Haeberle S, "Regulatory t-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease", J Allergy Clin Immunol, 142, pp.1831~1842 (2018)
96. McGinness JL, "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome(IPEX)associated with pemphigoid nodularis : a case report and review of the literature", J Am Acad Dermatol, 55, pp.143~148 (2006)
97. Joly P, "A comparison of oral and topical corticosteroids in patients with bullous pemphigoid", N Engl J Med, 346, pp.321~327 (2002)
98. Feliciani C, "Management of bullous pemphigoid : the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology", Br J Dermatol, 172, pp.867~877 (2015)
99. Williams HC, "Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid : a pragmatic, non-inferiority, randomised controlled trial", Lancet, 389, pp.1630~1638 (2017)
100. Sticherling M, "An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone", Br J Dermatol, 177, pp.1299~1305 (2017)
101. 박찬수, "Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines", Immune Network, 20(6), pp.1~13 (2020), 대한면역학회[DOI]
102. Yoo DS, "Mortality and clinical response of patients with bullous pemphigoid treated with rituximab", Br J Dermatol, 185, pp.210~212 (2021)
103. Amagai M, "A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid", J Dermatol Sci, 85, pp.77~84 (2017)
104. De D, "Omalizumab : an underutilized treatment option in bullous pemphigoid patients with co-morbidities", J Eur Acad Dermatol Venereol, 35, pp.e469~e472 (2021)
105. Freire PC, "Specific inhibition of the classical complement pathway prevents c3 deposition along the dermal-epidermal junction in bullous pemphigoid", J Invest Dermatol, 139, pp.2417~2424 (2019)
106. Mirzoyev SA, "Lifetime incidence risk of alopecia areata estimated at 2. 1% by Rochester Epidemiology Project, 1990–2009", J Invest Dermatol, 134, pp.1141~1142 (2014)
107. Trüeb RM, "Alopecia areata : a comprehensive review of pathogenesis and management", Clin Rev Allergy Immunol, 54, pp.68~87 (2018)
108. Martinez-Mir A, "Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata", Am J Hum Genet, 80, pp.316~328 (2007)
109. Eckert J, "The pathogenesis of alopecia areata", Br J Dermatol, 80, pp.203~210 (1968)
110. Whiting DA, "Histopathologic features of alopecia areata : a new look", Arch Dermatol, 139, pp.1555~1559 (2003)
111. Paus R, "The hair follicle and immune privilege", J Investig Dermatol Symp Proc, 8, pp.188~194 (2003)
112. Bodemer C, "Role of cytotoxic T cells in chronic alopecia areata", J Invest Dermatol, 114, pp.112~116 (2000)
113. Gilhar A, "Frontiers in alopecia areata pathobiology research", J Allergy Clin Immunol, 144, pp.1478~1489 (2019)
114. Petukhova L, "Genome-wide association study in alopecia areata implicates both innate and adaptive immunity", Nature, 466, pp.113~117 (2010)
115. Xing L, "Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition", Nat Med, 20, pp.1043~1049 (2014)
116. Ito T, "Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack", J Invest Dermatol, 128, pp.1196~1206 (2008)
117. Borcherding N, "A transcriptomic map of murine and human alopecia areata", JCI Insight, 5, pp.e137424~ (2020)
118. Lee H, "Significance of bystander t cell activation in microbial infection", Nat Immunol (2021)[DOI]
119. Freyschmidt-Paul P, "Interferon-gamma-deficient mice are resistant to the development of alopecia areata", Br J Dermatol, 155, pp.515~521 (2006)
120. Rajabi F, "Alopecia areata : a review of disease pathogenesis", Br J Dermatol, 179, pp.1033~1048 (2018)
121. Alkhalifah A, "Alopecia areata update : part II. Treatment", J Am Acad Dermatol, 62, pp.191~202 (2010)
122. Kim BJ, "Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata", J Dermatolog Treat, 19, pp.216~220 (2008)
123. Joly P, "The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis", J Am Acad Dermatol, 55, pp.632~636 (2006)
124. Gordon PM, "Topical diphencyprone for alopecia areata : evaluation of 48 cases after 30 months’ follow-up", Br J Dermatol, 134, pp.869~871 (1996)
125. Uchiyama M, "Multivariate analysis of prognostic factors in patients with rapidly progressive alopecia areata", J Am Acad Dermatol, 67, pp.1163~1173 (2012)
126. Wang EH, "Jak inhibitors for treatment of alopecia areata", J Invest Dermatol, 138, pp.1911~1916 (2018)
127. Leonard WJ, "Cytokine receptor signaling pathways", J Allergy Clin Immunol, 105, pp.877~888 (2000)
128. Schwartz DM, "JAK inhibition as a therapeutic strategy for immune and inflammatory diseases", Nat Rev Drug Discov, 17, pp.78~ (2017)
129. Liu LY, "Tofacitinib for the treatment of severe alopecia areata and variants : a study of 90 patients", J Am Acad Dermatol, 76, pp.22~28 (2017)
130. Almutairi N, "Janus kinase inhibitors for the treatment of severe alopecia areata : An open-label comparative study", Dermatology, 235, pp.130~136 (2019)
131. King B, "Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata : Phase 2 results from a randomized controlled study", J Am Acad Dermatol, 85, pp.847~853 (2021)
132. King B, "A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata : 24-week results", J Am Acad Dermatol, 85, pp.379~387 (2021)

관련 논문AI추천